Literature DB >> 3231921

Idiopathic retinal gliosis mimicking a choroidal melanoma.

J A Sahel1, A R Frederick, R Pesavento, D M Albert.   

Abstract

A 37-year-old woman has followed for more than 10 years with an amelanotic peripheral intraocular tumor. This solitary lesion grew slowly and, because of the possibility of an amelanotic melanoma, the eye was enucleated. Histopathology revealed a localized "massive" retinal gliosis (MRG). Immunohistochemical staining for S-100 protein and glial fibrillary acidic protein (GFAP) were positive. Electron microscopy showed a highly fibrillar component and basement membrane formation in the extracellular space. Proliferating cells contained abundant fine filaments. These findings confirmed the glial origin of the proliferating cells. The previously undefined relationship of these localized forms of MRG with solitary astrocytomas is discussed.

Entities:  

Mesh:

Year:  1988        PMID: 3231921     DOI: 10.1097/00006982-198808040-00011

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  4 in total

1.  Massive retinal gliosis: a late complication of retinal detachment surgery.

Authors:  Faik Gelisken; Werner Inhoffen; Jens Martin Rohrbach; Karl Ulrich Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-02-10       Impact factor: 3.117

2.  Vasoproliferative tumours of the retina.

Authors:  H Heimann; N Bornfeld; O Vij; S E Coupland; N E Bechrakis; U Kellner; M H Foerster
Journal:  Br J Ophthalmol       Date:  2000-10       Impact factor: 4.638

3.  Massive retinal gliosis: an unusual case with immunohistochemical study.

Authors:  Sanjay D Deshmukh; Amrut V Ashturkar; Shridhar V Babanagare; Suvarna K Gokhale; Anand A Deshpande
Journal:  Indian J Ophthalmol       Date:  2011 May-Jun       Impact factor: 1.848

4.  Ruthenium-106 plaque brachytherapy for symptomatic vasoproliferative tumours of the retina.

Authors:  G Anastassiou; N Bornfeld; A O Schueler; H Schilling; S Weber; D Fluehs; B Jurklies; O Vij; W Sauerwein
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.